Replies to post #1130 on GTC Biotherapeutics (fka GTCB)

[shears]

The question I have about the LFB deal is whether the future value of the shares sold is roughly equal to the cash gained and future revenues minus expenses? They could have diluted by other means to raise cash or raised cash with development deals. Where will GTCB's market cap be in 2013? Between now and then how many other protein production/royalty deals will be in place and producing revenue? Is 50% of what LFB has to offer that valuable? GTCB must think so. I think they blew their wad in terms of dilution with this deal. I hope they know what they're doing and what the true potential of this deal is beyond factor VII. It better be big because as I see it they gave up alot for a measely $25M. I'll hold what I have but I'm tired of being diluted and I am less likely to add to what I have till I see some more deals and revenue streams come to fruition.

[DewDiligence]

>…have you voiced your concerns to Tom Newberry about the LFB deal? By concerns I mean the dilution and except for the 25 million (as a result of the dilution) the lack of any near term prospects.<

Tom reads this board, so he already knows what I think about the deal.

I talk to Tom often to seek clarification and occasionally to correct misstatements or offer suggestions. I don't complain about events that have already occurred.

>what questions do you have for the next conference call…<

There’s still a month to go before the 3Q06 CC in early November, so we have plenty of time to think about this in the coming weeks. Regards, Dew